 |
| ABLYNX (D) |
|
|
|
|
| Codes and classification |
|
| ISIN |
BE0003877942 |
Mnemo |
ABLX |
CFI |
ESVUFN |
|
|
|
| Market |
EURONEXT BRUSSELS - Euronext - Local Securities |
| Type |
Stock - Ordinary stock - Continuous |
Compartment B (Mid Caps) |
|
|
|
|
|
|
|
| ICB sectorial classification |
|
|
|
|
|
| Activity |
Ablynx specializes in the research and development of nanobodies (therapeutic proteins made from natural antibody fragments) intended to improve treatments for inflammatory diseases, thrombosis, cancer, and Alzheimer's disease. Net sales break down by income as follows:
- revenues from partnership agreements (92.8%);
- subsidies (7.2%).
|
|
| Source: COFISEM - Last update: 12/11/09 |
|
|
|
|
|
| Key figures |
| Millenium |
2008 |
2007 |
2006 |
| Revenue* |
16,755 |
9,920 |
3,969 |
| Operating profit* |
-20,575 |
-14,307 |
-13,647 |
| Net profit |
-15,223 |
-12,522 |
-13,233 |
| Shareholder's equity |
93,870 |
108,175 |
20,051 |
| Total assets |
126,523 |
134,336 |
30,672 |
| Fiscal year end |
12.08 |
12.07 |
12.06 |
| Length of fiscal year (months) |
12 |
12 |
12 |
| Currency & Unit |
EUR - THOUSANDS |
EUR - THOUSANDS |
EUR - THOUSANDS |
| Account standards |
IFRS |
IFRS |
IFRS |
|
|
Source:
COFISEM -
Last update:
12/11/09 |
|
|
|
|
|
|
|
|
Ablynx
Technologiepark 4
9052 Zwijnaarde
Belgium
Phone number:+32 (0)9 262 00 00
Fax:+32 (0)9 262 00 01
http://www.ablynx.com
|
|
|
|
|
|
| Company contact |
Wim Ottevaere
investors@ablynx.com
Phone number:00 32 9 262 00 00
|
|
Source:
ABLYNX (D)
- Last update: 19/02/09 |
|
|
|
|
|
|
|
| Top management |
| Chairman and Chief Executive Officer |
Edwin Moses |
| Chief Business Officer |
Eva-Lotta Allan |
| Chief Medical Officer |
Josefin-Beate Holz |
| Chief Scientific Officer |
Debbie Law |
| Chief Financial Officer |
Wim Ottevaere |
| Investor Relations |
Wim Ottevaere |
|
|
Source:
COFISEM
- Last update: 12/11/09 |
|
|
|
|
|
|
| Shareholders |
| GIMV |
19.7 % |
| Sofinnova Capital IV |
16.27 % |
| Abingworth Bioventures |
11.26 % |
| ACP IV |
8.61 % |
| Gilde |
8.07 % |
| Boehringer-Ingelheim |
5.88 % |
| Nederlandia Investments and Multifund |
5.21 % |
| KBC Private Equity |
4.36 % |
| Vlaams Interuniversitair Instituut voor Biotechnologie |
3.77 % |
| KBC Asset Management |
3.42 % |
|
|
Source:
COFISEM
- Last update: 12/11/09 |
|
|
|
|
|
|
|
|
|
|
| |
Some explanations on the accounts
Net profit:
The net (after tax) profit for the entire group as a whole.
This includes the Group's share of the net profit, as well as
the net profit for the minority interests.
IAS-IFRS standard
2005 accounts for companies listed on Eurolist are in
the IAS-IFRS accounting standard. Companies
listed on a regulated market are under the obligation to publish
their 2005 aggregated accounts in the IAS-IFRS standard.
Data in IAS-IFRS standard
In the « Bank » sector, the « Net sales » corresponds to « Revenues
» (or « Net sales »)
In the "Insurance" sector, the « Premiums» corresponds to the
« Revenues » (or « Net sales »).
In the "Listed property trusts" sector, the « Gross rental income»corresponds
to the « Revenues » (or « Net sales »).
In the "Société de Portefeuille" sector, the « Income» corresponds
to the « Revenues » (or « Net sales »).
Data in local standard
*Those data are based on the Accounting standards in force in
the "Industry" sector, excepted for some anglo-saxon listed
companies which use "Operating profit" instead of "Operating
income".
In the « Bank » sector, the « Net banking incomes » corresponds
to « Revenues » (or « Net sales »).
In the "Insurance" sector, the « Premiums» corresponds to the
« Revenues » (or « Net sales »).
In the other sectors with a specific activity, the « Investment
revenues» corresponds to the « Revenues » (or « Net sales »),
the « Operating income » to the « Operating profit ».
|
|
|
|
|
